Treatment Resistant Depression Market Growth Accelerated By Rising Prevalence Of Treatment Resistant Depression
![]() |
Treatment Resistant Depression Market |
Treatment resistant depression refers to depression that does not respond to at
least two antidepressant treatments of adequate dose and duration in the
current episode. It is associated with serious functional impairment and
increased medical costs. Patients suffering from treatment resistant depression
opt for alternative therapies such as psychotherapy, somatic treatments
including electroconvulsive therapy, and novel pharmacological therapies. The
global Treatment Resistant Depression Market is estimated to be valued at US$
1220.12 Mn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023 to 2030, as highlighted
in a new report published by Coherent Market Insights.
Market key trends:
The rising prevalence of treatment resistant depression across the globe is the
major factor driving the growth of this market. As per the WHO, over 264
million people suffer from depression worldwide. Close to 30% of individuals
with MDD have treatment-resistant depression. Moreover, the introduction of
novel therapeutics in the pipeline is also expected to boost the treatment
resistant depression market growth over the forecast period. For instance,
companies are developing psychedelic drugs such as psilocybin, ketamine, and
MDMA for treatment resistant depression. These new therapeutic modalities have
shown encouraging results in treatment resistant patients by changing
neuroplasticity and promoting neurogenesis. Furthermore, rising awareness
regarding alternative therapies such as transcranial magnetic stimulation and
vagus nerve stimulation is also contributing to the market growth.
Segment
Analysis
The global
treatment resistant depression market is segmented based on treatment type,
application, and end user. Based on treatment type, the ketamine segment
dominates the market due to increased success rate of ketamine treatment in
reducing depression symptoms. Ketamine therapy works by changing brain
functions and helping formation of new neural connections.
Key Takeaways
The global
treatment resistant depression market analysis is expected to witness
high growth over the forecast period. Increasing prevalence of depression and
lack of effective treatment options is driving the growth of this market.
Regional analysis: North America
region currently dominates the global market due to favorable reimbursement
policies and increasing healthcare expenditure. The United States accounts for
a major share in the North American market. Asia Pacific region is expected to
witness fastest growth during the forecast period owing to rising awareness and
improving healthcare infrastructure in countries like China and India.
Key players operating in the treatment resistant depression market are
HempFlax, Cavac Biomateriaux, BaFa, Hemp Planet, Dunagro, American Hemp,
Hempline, Hemp Inc, Ecofibre, GenCanna, Hemp Oil Canada, Hemp Poland, Plains
Industrial Hemp Processing, Colorado Hemp Works, MH Medical Hemp, Hempco,
Hempfield Farms, Hemp Tech, Tilray, Canopy Growth. These companies are focusing
on new product launches and increasing production capacities to strengthen
their market position.
Get
more insights on this topic: https://www.newswirestats.com/treatment-resistant-depression-market-industry-insights-trends-treatment-resistant-depression-market/
Explore
more information on this topic, Please visit: https://www.newsintv.com/health/crispr-and-cas-gene-a-revolutionary-gene-editing-technology/
Comments
Post a Comment